Moreover, the SUMO-C1 group showed a higher expression of co-stimulatory and MHC molecules and lower expression of co-inhibitory molecules (Figures 4E–G), such as CD274, PDCD1, and LAG3, which are now commonly used as immunotherapeutic checkpoints in lung adenocarcinoma. The gene discussed is HLA-C; the disease is lung adenocarcinoma.